Member Info for sadoldgit

From March this year:-

Licensed Programme - SRA737: A Selective Chk1 inhibitor



SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint Kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and central mediator of the DNA Damage Response (DDR) network.



SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research (London, UK) in collaboration with Sareum, and with funding from Cancer Research UK ("CRUK").



CRT Pioneer Fund ("CPF"), which is dedicated to financing assets and companies including projects derived from CRUK's oncology drug discovery portfolio, licensed SRA737 to the Nasdaq-listed company Sierra Oncology in 2016. In return, CPF is eligible for up to US$328.5 million, including an upfront payment of US$7 million and US$321.5 million payable upon the achievement of certain development, regulatory and commercial milestones, plus royalties on future sales.



CPF has a Co-investment and Partnership agreement with Sareum, under which Sareum is eligible to receive 27.5% of all payments made to CPF as SRA737 advances, equivalent to up to a total of US$88 million in future milestone payments, plus sales royalties.



SRA737 - Current Status

The development work that Sierra has conducted has positioned SRA737 as potentially one of the leading clinical assets targeting the DDR pathway. During 2019, Sierra presented positive safety & efficacy of SRA737+low-dose gemcitabine (LDG) from a broad Phase 1/2 clinical development programme supporting standalone development in anogenital cancer. In addition, compelling preclinical data was presented supporting the use of SRA737 in combination with novel therapeutic approaches that are gaining traction as mainstays of targeted cancer treatment, including PARP inhibitors and immune checkpoint blockade.

I had forgotten about the CPF bust here is an extract from 2013

The Cancer Research Technology Pioneer Fund (CPF), London Stock Exchange-listed investment company, BACIT Limited (BACIT), and drug discovery company, Sareum Limited (Sareum), have entered into an agreement to co-fund the further development of a class of cancer drugs called CHK1 inhibitors.

The candidate inhibitor originates from research in the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, by scientists funded by Cancer Research UK working alongside Sareum’s researchers, and in collaboration with Cancer Research Technology (CRT).

A significant proportion of the further work funded by this new investment will be carried out at The Institute of Cancer Research (ICR), and it is expected that the drug candidate will be taken into clinical development at The Royal Marsden NHS Foundation Trust.

The rights to the preclinical programme have been licensed into CPF from CRT and the ICR. Under the terms of the deal, CPF obtains worldwide rights to the preclinical CHK1 inhibitor programme and is responsible, for future development and commercialisation, funded by CPF, BACIT and Sareum. CRT and the originating research partners, Sareum and the ICR, are entitled to an up-front fee plus success milestone and royalty payments. Financial terms of the licence are not disclosed.

The investment is the first by BACIT in a drug development or medical innovation project at the ICR.

CHK1 inhibitors control a cancer cell’s response to DNA damage. Blocking CHK1 could boost the efficacy of chemotherapy drugs by blocking repair of the DNA damage caused by these drugs, but without harming healthy cells.

The developers of the programme believe the candidate CHK1 inhibitor to be developed could potentially treat a range of cancers including pancreatic, bowel and non-small cell lung cancer (NSCLC) in combination with DNA-damaging chemotherapy drugs and radiotherapy. The inhibitor could also potentially treat certain neuroblastoma and acute myeloid leukaemia (AML) types when dosed alone.

Ian Miscampbell, managing partner of Sixth Element Capital, the Manager of CPF, said: “This is the third investment made by the £50M CPF which CRT and the European Investment Fund launched in 2012 to bridge the UK funding gap between cancer drug discovery and early treatment development.

Interjecting here, Tim stated they would recieve decision on a grant for C-19 due in October. Not sure when in October but l dont recall him saying by October. It was the Interviee he had with the smooth talking Aussie.

I am with you 100% on that one Potnak. There is nothing anyone can say until it happens.

Yes,Bas, l would. Sierra have not been very forthcoming with updates. It is as if they want to put a low profile on it. SRA 737 was taken out the shop window around 3 months ago. Are they trying to raise funds to continue development themselves or have they found a company to license to. Negotiations for licensing highly unlikely to be completed within a 3 month period especially in the current climate. If they are in negotiations then we will never get to hear about until the deal is done. Regards

If Sierra want to choose to be awkward then tell me please what exactly SAR or the ICR can do. The threat of legal action? In the U S of A with the current C 19 it would take months /years. Costs run into hundreds of thousands of dollars. I believe Sierra have until the end of September to 5h1 t or get off the bucket.

737 belongs to ICR. Sareum are entitled to 27% of milestone payments and Royalties and as such carry very little sway.

I am aware that their has been progress in the reduction of Nitrogen oxides but would be very interested to know how they can claim to get down to virtually zero. I know they have 3 way cats on petrol engines but don't know of any on diesels as have not been able to achieve hot enough cat temperatures (I could be wrong and very often am). NO2 as a greenhouse gas is considered 300 times more harmful to the environment than CO2. The push for diesel? When there were few diesels about ( many years ago the price of diesel was cheaper than petrol. Price of diesel now around the same price as petrol after being several p per litre higher.
I agree whole heartedly with your view on the mining of elements for the purposes of the EV battery. They need work out how to recycle them if indeed it is possible.

It is summer time and yes we are not at full capacity. The point I make is, base load mainly being nuclear then you can bring in additional power supply generally gas powered but also wind and solar. ( we still have operational coal fired power stations left but are due to be phased out). The problem with wind and solar is they are not very controllable and hence not good at supplying constant load to the grid. Get load distribution wrong and you can take out the whole grid!

Should the EPWR at Hinkley Pt get delayed then country could end up in a dire mess. Closure of the AGR's at Dungeness Hinkley pt,, Heysham (2) Hartlepool, Hunterston ( which is suffering from graphite degradation) and Torness, will just leave Sizewell B at 1188 Mw(e)
Where are we going to get the electric from? We have for years been importing it from France typically 2 GW and this is the first time I have seen (0.9 GW) any suggestion of the UK supplying the French ( over 70% nuclear powered) with electric that is news to me. The original agreement when made only allowed the supply of electricity to go one way!
The point I am making is we would not be able to produce enough electricity for the charging of several million electric cars. The grid and power generation could not support the non consistent load at this time or any time in the near future.
Look forward to winter when the generation will be in demand from the handful of operational coal fired power stations. The internal combustion engine will be good for a few more years yet. Cannot see that this is in anyway a threat in anyway to the DBX.

Regards

Yes DH agree, but they also stated that ' SRA737 could prove to be more commercially viable than Momoletinib'. There were drastic cut backs from angles including a 5.2 million dollar cut back on SRA 737 to enable them to pursue Momoletinib. They cant afford to keep it but at the same time I feel they dont want anyone else to have it either. You can't call the shots when you dont have any money. It has all been kept low key. On the plus side they have carried out some great work with the time they have had the CHK 1 compound. Heritage is good with the CHK1 being developed by the ICR ( you wont find much better than that anywhere in the world), the involvement of Michelle Garrett and of course SAR who are very good at chemistry.
All we can do is wait on news, not only for this but also Flt=3 and 1801/1802.
Not sure what news we get next but I would hazzard a guess at the Covid-19 grant, Sr737 and the FLt3.

A good bit of the basic info here to understand our immune systems and how they detect or do not detect viruses, nothing above anybodies pay scale of course.

https://www.immunology.org/public-information/bitesized-immunology/pathogens-and-disease/immune-responses-viruses
Regards

Good spot Krone. It most likely they have an interested party or parties already. It could only be for 1802/1802 and as we know are awaiting the MTD. As for a new patent we have no option but to wait and see. It is anybody's call on this and the worst case scenario is it is still protected under the original TYK2 patent. as you well know. In addition, I would add is the applied for C-19 grant of which Sareum and of ourselves in due course are informed of the outcome.
Regards

One way of looking at it there are many shares bought at sub .6p. Many may have limits put on at just over the penny. If large buys come in the price would rise and considerable sells could be executed by just going over the penny. When news does arrive the price will rocket giving mms a load of shares on the cheap.any positive news of any sort will send this north of 1.5p. Just my opinion
Regards all

Decision due October.

Working in pharma, l think you have hit the nail on the proverbial head. Nothing more than their attempt to decamp. No facts just arguement from their side trying to justify their previous comments. Note their use of implied words now as instead of a direct ,' sar needs to raise funds'. Then we get a very pathetic ,' what else can a company do ' type response. For a start:- Income from Sra 737 milestone and or FLT+3 are alternatives albeit not guaranteed. With recently joining and very little knowledge their only objective is to decamp in a vain attempt to get in on the cheap.

No, Sar have not said they need to raise funds. They may and most likely will require funds for further development of 1801 but at the present have sufficient funds for next 12 months. So l ask again where have they stated that they need to raise funds?

On what basis do you make such an absurd claim?

Not quite as promising as they thought.

Yes JFF it is a straight comment from Krone. However, can not see ICR taking it back whilst patients still receiving treatment. Treatment still being administered to patients with advanced cancers speaks volumes for the potential of SRA737. I gather Sierra are after a 150 million dollar funding. Dependant on negotiations with CPF I would hazard a guess that a milestone payment of some sort would be negotiated. It has just been one way traffic with Sierra clinging onto Chk1 which is most likely a better commercialisation opportunity than the momoletonib. As long as funds if and when raised are used for Sra 737 and not Momeletonib, then all should bode well.

That is a strange post to put after your recent post:-
'Here here evidence of buyout and game changing amount of money coming soon l would not part with my 8 million until the beautiful lady sings... daffodils if you do!!!!!'
At the end of the day it is your choice. I will keep my 8 million and should price fall will add.